<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Almatrafi A</submitter><funding>National Institute for Health Research (NIHR)</funding><pagination>3-13</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9925896</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(1)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Comorbidity is associated with adverse outcomes for all lung cancer patients, but its burden is less understood in the context of screening. This review synthesises the prevalence of comorbidities among lung cancer screening (LCS) candidates and summarises the clinical recommendations for screening comorbid individuals.&lt;h4>Methods&lt;/h4>We searched MEDLINE, EMBASE, EBM Reviews, and CINAHL databases from January 1990 to February 2021. We included LCS studies that reported a prevalence of comorbidity, as a prevalence of a particular condition, or as a summary score. We also summarised LCS clinical guidelines that addressed comorbidity or frailty for LCS as a secondary objective for this review. Meta-analysis was used with inverse-variance weights obtained from a random-effect</pubmed_abstract><journal>Journal of medical screening</journal><pubmed_title>The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.</pubmed_title><pmcid>PMC9925896</pmcid><funding_grant_id>ACF-2020-02-004</funding_grant_id><pubmed_authors>Thomas O</pubmed_authors><pubmed_authors>Gabe R</pubmed_authors><pubmed_authors>Neal R</pubmed_authors><pubmed_authors>Almatrafi A</pubmed_authors><pubmed_authors>Callister M</pubmed_authors><pubmed_authors>Beeken RJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.</name><description>&lt;h4>Objective&lt;/h4>Comorbidity is associated with adverse outcomes for all lung cancer patients, but its burden is less understood in the context of screening. This review synthesises the prevalence of comorbidities among lung cancer screening (LCS) candidates and summarises the clinical recommendations for screening comorbid individuals.&lt;h4>Methods&lt;/h4>We searched MEDLINE, EMBASE, EBM Reviews, and CINAHL databases from January 1990 to February 2021. We included LCS studies that reported a prevalence of comorbidity, as a prevalence of a particular condition, or as a summary score. We also summarised LCS clinical guidelines that addressed comorbidity or frailty for LCS as a secondary objective for this review. Meta-analysis was used with inverse-variance weights obtained from a random-effect</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-18T21:30:43.086Z</modification><creation>2025-04-07T09:21:00.576Z</creation></dates><accession>S-EPMC9925896</accession><cross_references><pubmed>35942779</pubmed><doi>10.1177/09691413221117685</doi></cross_references></HashMap>